ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce ...
Developing innovative peptide drugs to fight specialist diseases
ImmuPharma is an evolving speciality biopharmaceutical company.
We are developing an innovative portfolio of novel peptide-based therapeutic drugs, or Bio-drugs, focusing on Autoimmunity/Inflammation and Anti-Infectives.
Unlocking value through licensing, partnering and collaborations.
Creating near term shareholder value with our lead asset, Lupuzor™ as it moves through its Phase 2/3 adaptive study.
BioPharma: Peptides are naturally occurring biological molecules built from our body’s amino acids. Peptides also represent a unique class of biopharmaceutical therapeutics, molecularly poised between small molecules and proteins, yet biochemically and therapeutically distinct from both. With expertise in peptide innovation, ImmuPharma is focused on delivering safe and efficacious peptide-based Bio-drugs through its Bordeaux subsidiary ImmuPharma Biotech.
Our focus and expertise within R&D are:
Creation: Our core mission is to create a targeted and enriched pipeline of peptide-based biopharmaceuticals or Bio-drugs. Our lead candidate LupuzorTM for Lupus is at Phase 3.
Our team is committed to the creation of significant improvements on existing therapies for targeted diseases. Our new Bio-drug development is created for long term shareholder value.
Evolution: requires the need for positive change. Our inspirational and achievable goals include:
- An innovative R&D team focused on commercially attractive and achievable targets
- A more focused Bio-drug portfolio
- Alignment with expert collaborators & licensing/partners relevant to the development and commercialisation of our Bio-drugs
- Pipeline depth and breadth to create opportunities for near term revenue generation
*Phase 2/3 adaptive trial becomes a pivotal trial for filing